Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Toni K. Choueiri(Harvard University), Neeraj Agarwal(University of Utah), Judit Kocsis(Bács-Kiskun Megyei Kórház), Kouros Owzar(Duke University), Yingmiao Liu(Duke Medical Center), Sumanta K. Pal(City of Hope), Andrew B. Nixon(Duke University), Yousef Zakharia(University of Iowa), Meghara Walsh(Dana-Farber Cancer Institute), Thai H. Ho(Mayo Clinic in Arizona), Charles P. Theuer(Halozyme Therapeutics (United States)), Mark D. Starr(Duke Medical Center), Jing Lyu(University College Dublin), Alexandr Poprach(Masaryk University), Primo N. Lara(UC Davis Comprehensive Cancer Center), Russell K. Pachynski, Lajos Géczi(National Institute of Oncology), Bonne J. Adams(Tracon Pharmaceuticals (United States)), Mohamed Darif(Biogen (United States)), Liz Robertson(Tracon Pharmaceuticals (United States)), Mollie deShazo(University of Alabama at Birmingham)
Cited by 10
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k